82 related articles for article (PubMed ID: 20796145)
1. Reversal of the tolerance phenomenon by the intermittent administration of a histamine H2-receptor antagonist.
Takahashi M; Katayama Y
J Gastroenterol Hepatol; 2010 Sep; 25(9):1493-7. PubMed ID: 20796145
[TBL] [Abstract][Full Text] [Related]
2. Helicobacter pylori infection prevents the occurrence of the tolerance phenomenon of histamine H2 receptor antagonists.
Fujisawa T; Adachi K; Komazawa Y; Mihara T; Azumi T; Katsube T; Furuta K; Kazumori H; Kinoshita Y
Aliment Pharmacol Ther; 2004 Sep; 20(5):559-65. PubMed ID: 15339327
[TBL] [Abstract][Full Text] [Related]
3. Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administration.
Lachman L; Howden CW
Am J Gastroenterol; 2000 Jan; 95(1):57-61. PubMed ID: 10638559
[TBL] [Abstract][Full Text] [Related]
4. Effect of Helicobacter pylori status on intragastric pH during administration of lafutidine or famotidine.
Koike T; Ohara S; Sehine H; Kawamura M; Abe Y; Inomata Y; Iijima K; Imatani A; Shimosegawa T
Hepatogastroenterology; 2007 Jun; 54(76):1280-4. PubMed ID: 17629089
[TBL] [Abstract][Full Text] [Related]
5. Effects of a novel histamine H2-receptor antagonist, lafutidine, on the mucus barrier of human gastric mucosa.
Ichikawa T; Ota H; Sugiyama A; Maruta F; Ikezawa T; Hotta K; Ishihara K
J Gastroenterol Hepatol; 2007 Nov; 22(11):1800-5. PubMed ID: 17914953
[TBL] [Abstract][Full Text] [Related]
6. Tolerance to H2 receptor antagonist correlates well with the decline in efficacy against gastroesophageal reflux in patients with gastroesophageal reflux disease.
Furuta K; Adachi K; Komazawa Y; Mihara T; Miki M; Azumi T; Fujisawa T; Katsube T; Kinoshita Y
J Gastroenterol Hepatol; 2006 Oct; 21(10):1581-5. PubMed ID: 16928220
[TBL] [Abstract][Full Text] [Related]
7. Immediate acid-suppressing effects of ranitidine hydrochloride and rabeprazole sodium following initial administration and reintroduction: A randomized, cross-over study using wireless pH monitoring capsules.
Ono S; Kato M; Ono Y; Imai A; Yoshida T; Shimizu Y; Asaka M
J Gastroenterol Hepatol; 2009 Apr; 24(4):639-45. PubMed ID: 19032447
[TBL] [Abstract][Full Text] [Related]
8. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough.
Mainie I; Tutuian R; Castell DO
J Clin Gastroenterol; 2008 Jul; 42(6):676-9. PubMed ID: 18496394
[TBL] [Abstract][Full Text] [Related]
9. Lafutidine prevents low-dose aspirin and loxoprofen induced gastric injury: a randomized, double-blinded, placebo controlled study.
Kato M; Kamada G; Yamamoto K; Nishida U; Imai A; Yoshida T; Ono S; Nakagawa M; Nakagawa S; Shimizu Y; Asaka M
J Gastroenterol Hepatol; 2010 Oct; 25(10):1631-5. PubMed ID: 20880171
[TBL] [Abstract][Full Text] [Related]
10. A new-generation H2 receptor antagonist: quicker and stronger acid inhibition than proton pump inhibitors in the clinical setting?
Tsuji S; Kawano S
J Gastroenterol; 2005 May; 40(5):549-50. PubMed ID: 15942726
[No Abstract] [Full Text] [Related]
11. Stronger inhibition of gastric acid secretion by lafutidine, a novel H2 receptor antagonist, than by the proton pump inhibitor lansoprazole.
Yamagishi H; Koike T; Ohara S; Horii T; Kikuchi R; Kobayashi S; Abe Y; Iijima K; Imatani A; Suzuki K; Hishinuma T; Goto J; Shimosegawa T
World J Gastroenterol; 2008 Apr; 14(15):2406-10. PubMed ID: 18416470
[TBL] [Abstract][Full Text] [Related]
12. Early effects of oral administration of lafutidine with peppermint oil, compared with lafutidine alone, on intragastric pH values.
Iida H; Inamori M; Uchiyama T; Endo H; Hosono K; Akiyama T; Sakamoto Y; Fujita K; Takahashi H; Yoneda M; Koide T; Tokoro C; Goto A; Abe Y; Kobayashi N; Kirikoshi H; Kubota K; Saito S; Nakajima A
Hepatogastroenterology; 2011; 58(105):235-8. PubMed ID: 21510321
[TBL] [Abstract][Full Text] [Related]
13. Chronic administration of H2-antagonists does not alter gastric secretory responses to histamine, or the antisecretory activity of sufotidine.
Stables R; Humphray JM; Reeves JJ
Aliment Pharmacol Ther; 1990; 4 Suppl 1():7-13. PubMed ID: 1983348
[TBL] [Abstract][Full Text] [Related]
14. Lafutidine-based triple therapy for Helicobacter pylori eradication.
Ren Q; Ma B; Yang K; Yan X
Hepatogastroenterology; 2010; 57(102-103):1074-81. PubMed ID: 21410034
[TBL] [Abstract][Full Text] [Related]
15. Sofalcone, a gastroprotective drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori: a randomized controlled comparative trial with cimetidine, an H2-receptor antagonist.
Higuchi K; Watanabe T; Tanigawa T; Tominaga K; Fujiwara Y; Arakawa T
J Gastroenterol Hepatol; 2010 May; 25 Suppl 1():S155-60. PubMed ID: 20586860
[TBL] [Abstract][Full Text] [Related]
16. Early effects of oral administration of lafutidine with mosapride compared with lafutidine alone on intragastric pH values.
Iida H; Inamori M; Nozaki Y; Endo H; Hosono K; Akiyama T; Sakamoto Y; Takahashi H; Koide T; Tokoro C; Abe Y; Nakajima A
BMC Gastroenterol; 2009 Jul; 9():52. PubMed ID: 19589146
[TBL] [Abstract][Full Text] [Related]
17. Histamine-2 receptor expression in gastric mucosa before and after Helicobacter pylori cure.
Osawa H; Kita H; Ohnishi H; Mutoh H; Ishino Y; Satoh K; Sugano K
Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():92-8. PubMed ID: 15943854
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the effects of anti-secretory drugs on intragastric acidity: is combined therapy with a proton pump inhibitor and an H2 receptor antagonist effective as initial treatment?
Inamori M; Togawa J; Chiguchi G; Abe Y; Kikuchi T; Muramatsu K; Kawamura H; Kobayashi N; Kirikoshi H; Shimamura T; Sakaguchi T; Takamura T; Ueno N; Nakajima A
J Gastroenterol; 2005 Feb; 40(2):213-4. PubMed ID: 15770408
[No Abstract] [Full Text] [Related]
19. Do anticholinergics interact with histamine H2 receptor antagonists on night intragastric acidity in active duodenal ulcer patients?
Fiorucci S; Clausi GG; Farinelli M; Santucci L; Farroni F; Pelli MA; Morelli A
Am J Gastroenterol; 1988 Dec; 83(12):1371-5. PubMed ID: 2904218
[TBL] [Abstract][Full Text] [Related]
20. Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection.
Komazawa Y; Adachi K; Mihara T; Ono M; Kawamura A; Fujishiro H; Kinoshita Y
J Gastroenterol Hepatol; 2003 Jun; 18(6):678-82. PubMed ID: 12753150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
